Dr. Reiss is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1161 21st Ave South T-1218 Medical Center North
Vanderbilt University School Of Medicine
Nashville, TN 37232Phone+1 615-322-3773Fax+1 615-343-7448
Education & Training
- University of California (San Francisco)Residency, Neurological Surgery, 1992 - 1995
- University of California (San Francisco)Fellowship, Pulmonary Disease and Critical Care Medicine, 1986 - 1989
- Vanderbilt University Medical CenterResidency, Internal Medicine, 1983 - 1984
- Vanderbilt University School of MedicineClass of 1983
Certifications & Licensure
- NJ State Medical License 1991 - 2025
- TN State Medical License 2011 - 2013
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Pulmonary Disease
Publications & Presentations
PubMed
- 81 citationsMontelukast causes prolonged, potent leukotriene D4‐receptor antagonism in the airways of patients with asthmaInge De Lepeleire, Theodore F. Reiss, F Rochette, Albert Botto, Ji Zhang
Clinical Pharmacology and Therapeutics. 1997-01-01 - 14 citationsAn oral selective M3 cholinergic receptor antagonist in COPDSusan Lu, Darshan D. Parekh, Olga M. Kuznetsova, Stuart A. Green, Carol A. Tozzi
The European Respiratory Journal. 2006-10-01 - 259 citationsMontelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.Barbara Knorr, Luis Miguel Franchi, Hans Bisgaard, Jan Hendrik Vermeulen, Peter Lesouef
Pediatrics. 2001-09-01
Press Mentions
- Chutes & Ladders—Repertoire Immune Medicines, Buzzing from $189M Series B, Taps Celgene Vet as CMOJune 4th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: